Ülke: İrlanda
Dil: İngilizce
Kaynak: HPRA (Health Products Regulatory Authority)
ANAGRELIDE
Kent Pharmaceuticals Limited
L01XX35
ANAGRELIDE
0.5 Milligram
Capsules Hard
Product subject to prescription which may not be renewed (A)
anagrelide
Authorised
2018-04-20
150 mm 400 mm 15 mm 10 mm 29 mm A TEXT DIRECTION FRONT PAGE 17 mm 12 mm PHARMA CODE READING DIRECTION 10 mm 10 mm PACKAGE LEAFLET: INFORMATION FOR THE PATIENT ANAGRELIDE 0.5MG HARD CAPSULES Anagrelide This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • KEEP THIS LEAFLET. YOU MAY NEED TO READ IT AGAIN. • IF YOU HAVE FURTHER QUESTIONS, ASK YOUR DOCTOR OR PHARMACIST. • THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU ONLY. DO NOT PASS IT ON TO OTHERS. IT MAY HARM THEM, EVEN IF THEIR SIGNS OF ILLNESS ARE THE SAME AS YOURS. • IF YOU GET ANY SIDE EFFECTS TALK TO YOUR DOCTOR OR PHARMACIST. THIS INCLUDES ANY POSSIBLE SIDE EFFECTS NOT LISTED IN THIS LEAFLET. SEE SECTION 4. WHAT IS IN THIS LEAFLET 1. What Anagrelide is and what it is used for 2. What you need to know before you take Anagrelide 3. How to take Anagrelide 4. Possible side effects 5. How to store Anagrelide 6. Contents of the pack and other information IF YOU TAKE MORE ANAGRELIDE THAN YOU SHOULD If you take more Anagrelide than you should or if someone else has taken your medicine, tell a doctor or pharmacist immediately. Show them the pack of Anagrelide. IF YOU FORGET TO TAKE ANAGRELIDE Take your capsules as soon as you remember. Take your next dose at the usual time. Do not take a double dose to make up for a forgotten dose. POSSIBLE SIDE EFFECTS Like all medicines, Anagrelide can cause side effects, although not everybody gets them. If you are worried, speak to your doctor. _SERIOUS SIDE EFFECTS:_ Uncommon: Heart failure (signs include shortness of breath, chest pain, swelling of the legs due to fluid build-up), severe problem with the rate or rhythm of the heart beat (ventricular tachycardia, supraventricular tacycardia or atrial fibrillation), inflammation o Belgenin tamamını okuyun
SUMMARY OF PRODUCT CHARACTERISTICS This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1 NAME OF THE MEDICINAL PRODUCT Anagrelide 0.5 mg Hard Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains 0.5 mg anagrelide (as anagrelide hydrochloride monohydrate). Excipients with known effect: Each hard capsule contains lactose monohydrate (50.00 mg) and lactose anhydrous (37.14 mg) For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Hard capsule. A white hard capsule containing white to off-white fine powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at risk patient An at risk essential thrombocythaemia patient is defined by one or more of the following features: > 60 years of age or a platelet count > 1000 x 10 9 /l or a history of thrombo-haemorrhagic events 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment with Anagrelide should be initiated by a clinician with experience in the management of essential thrombocythaemia. Posology The recommended starting dose of anagrelide is 1 mg/day, which should be administered orally in two divided doses (0.5 mg/dose). The starting dose should be maintained for at least one week. After one week the dose may be titrated, on an individual basis, to achieve the lowest effective dose required to reduce and/or maintain a platelet count below 600 x 10 9 /l and ideally at levels between 150 x 10 9 /l and 400 x 10 9 /l. The dose increment must not exceed more than 0.5 mg/day in any one-week and the recommended maximum single dose should not exceed 2.5 mg (see section 4.9) Belgenin tamamını okuyun